Feedback / Questions
ATNM-400 - Actinium Pharmaceuticals
https://www.sahmcapital.com/news/content/actinium-pharmaceuticals-oral-presentation-at-snmmi-2026-highlights-atnm-400-overcoming-resistance-to-all-three-approved-androgen-receptor-inhibitors-and-offers-flexible-well-tolerated-dosing-in-prostate-cancer-models-2026-06-03
Jun 3, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next